| 9.555 -0.385 (-3.87%) | 06-29 11:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.77 | 1-year : | 14.92 |
| Resists | First : | 10.93 | Second : | 12.77 |
| Pivot price | 9.06  |
|||
| Supports | First : | 9.16 | Second : | 8.06 |
| MAs | MA(5) : | 9.74 |
MA(20) : | 8.89 |
| MA(100) : | 8.7 |
MA(250) : | 8.07 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 59.9 |
D(3) : | 72.7 |
| RSI | RSI(14): 59.2 |
|||
| 52-week | High : | 10.93 | Low : | 6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BCRX ] has closed below upper band by 27.9%. Bollinger Bands are 58.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.2 - 10.24 | 10.24 - 10.27 |
| Low: | 9.55 - 9.6 | 9.6 - 9.64 |
| Close: | 9.86 - 9.94 | 9.94 - 10 |
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Mon, 29 Jun 2026
BioCryst Pharmaceuticals (BCRX) Shifts Focus to External Innovat - GuruFocus
Mon, 29 Jun 2026
BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Mon, 29 Jun 2026
BioCryst (NASDAQ: BCRX) lowers 2026 expenses and closes Birmingham R&D hub - Stock Titan
Mon, 29 Jun 2026
BioCryst shuts Birmingham lab, cuts 2026 spending outlook - Stock Titan
Mon, 29 Jun 2026
BCRX Forecast — Price Target — Prediction for 2027 - TradingView
Mon, 29 Jun 2026
Enterprise value to revenue forward of BioCryst Pharmaceuticals, Inc. – NASDAQ:BCRX - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 254 (M) |
| Shares Float | 221 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 101.1 (%) |
| Shares Short | 40,640 (K) |
| Shares Short P.Month | 36,110 (K) |
| EPS | -1.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.19 |
| Profit Margin | -51.8 % |
| Operating Margin | -2.5 % |
| Return on Assets (ttm) | 42.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 7.5 % |
| Gross Profit (p.s.) | 2.67 |
| Sales Per Share | 3.48 |
| EBITDA (p.s.) | 1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 313 (M) |
| Levered Free Cash Flow | 264 (M) |
| PE Ratio | -5.41 |
| PEG Ratio | 9.3 |
| Price to Book value | -4.39 |
| Price to Sales | 2.74 |
| Price to Cash Flow | 7.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|